9,940 results match your criteria Factor X


Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.

Hematol Oncol Stem Cell Ther 2019 Mar 28;12(1):10-14. Epub 2018 Jun 28.

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address:

Introduction: Systemic light chain (AL) amyloidosis can lead to an acquired coagulopathy secondary to acquired factor X (aFX) deficiency. However, it is not very clear who develops aFX deficiency in AL amyloidosis.

Methods: We therefore undertook this single centre, retrospective study to better characterize AL amyloidosis-associated aFX deficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hemonc.2018.05.002DOI Listing

AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2-CDG.

Ann Neurol 2019 Mar 14. Epub 2019 Mar 14.

Genetic Medicine Department and Pediatric Institute of Rare Diseases, Institut de Recerca Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.

Objective: Phosphomannomutase deficiency (PMM2-CDG) causes cerebellar syndrome and stroke-like episodes (SLEs). SLEs are also described in patients with gain-of-function mutations in the CaV2.1 channel, for which acetazolamide therapy is suggested. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.25457DOI Listing
March 2019
1 Read

Severe Factor X Deficiency Presenting as Febrile Seizure in an Infant.

J Pediatr Hematol Oncol 2019 Mar 12. Epub 2019 Mar 12.

Department of Corneal Surgery and Ophthalmology, SK Soni Hospital, Jaipur, Rajasthan, India.

Factor X deficiency is a severe inherited coagulation disorder, which is characterized by severe systemic bleeding manifestations in affected individuals. It is a rare disorder with a frequency of around 1:1,000,000 in the general population. We present the case of an infant with factor X deficiency who presented with complex febrile seizure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001453DOI Listing
March 2019
1 Read

Effects of Oral Anticoagulant Therapy on Gene Expression in Crosstalk between Osteogenic Progenitor Cells and Endothelial Cells.

J Clin Med 2019 Mar 8;8(3). Epub 2019 Mar 8.

Department of Medicine, University of Verona, Pz.le Scuro 10, 37134 Verona, Italy.

Direct oral anti-coagulants (DOACs) are employed in clinical practice for the prevention and treatment of recurrent venous thromboembolism and for the prevention of stroke in non-valvular atrial fibrillation. DOACs directly and reversibly inhibit activated factor X or thrombin and can interfere with other pathophysiological processes such as inflammation, lipid metabolism, and bone turnover. We aimed to evaluate the possible effects of DOACs on osteogenesis and angiogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8030329DOI Listing
March 2019
1 Read

Elevated plasma levels of hepatocyte growth factor in rats experimentally envenomated with Bothrops jararaca venom: Role of snake venom metalloproteases.

Toxicon 2019 Mar 6;162:9-14. Epub 2019 Mar 6.

Laboratory of Pathophysiology, The Butantan Institute, Av. Dr. Vital Brazil 1500, CEP 05503-900, São Paulo, Brazil.

The hepatocyte growth factor (HGF)/c-met pathway, which mainly consists of HGF activator (HGFA) and its substrate HGF, protects various types of cells via anti-apoptotic and anti-inflammatory signals. Thrombin is the main physiological activator of such plasmatic pathway, and increased plasma concentrations of HGF have been considered as a molecular marker for some pathological conditions, such as disseminated intravascular coagulation. Since thrombin generation is often linked to tissue injury, and these events are common during snake venom-induced consumption coagulopathies (VICC), our goals were to examine whether Bothrops jararaca venom (Bjv), which induces VICC in vivo: (i) activates the HGF/c-met pathway in vivo and (ii) cleaves zymogen forms of HGFA and HGF (proHGFA and proHGF, respectively) in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxicon.2019.03.003DOI Listing
March 2019
1 Read

Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation.

Expert Opin Emerg Drugs 2019 Mar 7:1-7. Epub 2019 Mar 7.

a Institute of Applied Health Research , University of Birmingham , Birmingham , UK.

Introduction: Thromboembolic diseases are leading cause of mortality accounting for an estimated 1 in 4 deaths all over the world. Anticoagulation remains the mainstay of prevention and treatment of venous thromboembolic disorders. Conventional anticoagulants have been efficiently used over the last decades, but their clinical use encounters safety and convenience issues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2019.1591368DOI Listing
March 2019
1 Read

Genome-Wide Multiple Sclerosis Association Data and Coagulation.

Front Neurol 2019 14;10:95. Epub 2019 Feb 14.

Department of Neuroscience, Mental Health and Sensory Organs, Faculty of Medicine and Psychology, Centre for Experimental Neurological Therapies, S. Andrea Hospital, Sapienza University, Rome, Italy.

The emerging concept of a crosstalk between hemostasis, inflammation, and immune system prompt recent works on coagulation cascade in multiple sclerosis (MS). Studies on MS pathology identified several coagulation factors since the beginning of the disease pathophysiology: fibrin deposition with breakdown of blood brain barrier, and coagulation factors within active plaques may exert pathogenic role, especially through the innate immune system. Studies on circulating coagulation factors showed complex imbalance involving several components of hemostasis cascade (thrombin, factor X, factor XII). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.00095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383413PMC
February 2019
1 Read

A novel Kunitz protein with proposed dual function from Eudiplozoon nipponicum (Monogenea) impairs haemostasis and action of complement in vitro.

Int J Parasitol 2019 Feb 20. Epub 2019 Feb 20.

Department of Parasitology, Faculty of Science, Charles University, Viničná 7, 12844 Prague 2, Czech Republic. Electronic address:

Serine peptidases are involved in many physiological processes including digestion, haemostasis and complement cascade. Parasites regulate activities of host serine peptidases to their own benefit, employing various inhibitors, many of which belong to the Kunitz-type protein family. In this study, we confirmed the presence of potential anticoagulants in protein extracts of the haematophagous monogenean Eudiplozoon nipponicum which parasitizes the common carp. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpara.2018.11.010DOI Listing
February 2019

Direct oral anticoagulants for treatment of deep vein thrombosis: overview of systematic reviews.

J Vasc Bras 2018 Oct-Dec;17(4):310-317

University of Alberta, Edmonton, Canada.

A number of limitations of standard therapy with warfarin for deep vein thrombosis (DVT) have been established. This overview of systematic reviews presents the baseline results for efficacy and safety of the new direct oral anticoagulants (DOACs) thrombin inhibitors, and activated factor X (Xa) inhibitors in patients with DVT. Searches were run on PubMed and the Cochrane Database of Systematic Reviews. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1677-5449.005518DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375259PMC
February 2019
2 Reads

Haematological management of major bleeding associated with direct oral anticoagulants - UK experience.

Br J Haematol 2019 Feb 19. Epub 2019 Feb 19.

Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

The lack of antidotes for activated factor X-inhibitor direct oral anticoagulants (DOACs) means that management of bleeding consists largely of existing supportive therapies. This study aimed to: (i) examine the relative frequency of DOAC-related major bleeding in relation to DOAC prescriptions over the study period; (ii) describe the presentation and haematological management of DOAC-related major bleeding; and (iii) evaluate the association between the use of prothrombin-complex-concentrate (PCC) and in-hospital mortality. Over a 3-year period, 32 UK hospitals submitted data on haematological management of DOAC-related bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15808DOI Listing
February 2019
1 Read

PheWAS uncovers a pathological role of coagulation Factor X during infection.

Infect Immun 2019 Feb 19. Epub 2019 Feb 19.

Department of Pathology, Microbiology, & Immunology, Vanderbilt University Medical Center

Coagulation and inflammation are interconnected, suggesting coagulation plays a key role in the inflammatory response to pathogens. A Phenome-Wide Association Study (PheWAS) was used to identify clinical phenotypes of patients with a polymorphism in coagulation Factor X. Patients with this SNP were more likely to be hospitalized with hemostatic and infection-related disorders, suggesting Factor X contributes to the immune response to infection. Read More

View Article

Download full-text PDF

Source
http://iai.asm.org/lookup/doi/10.1128/IAI.00031-19
Publisher Site
http://dx.doi.org/10.1128/IAI.00031-19DOI Listing
February 2019
3 Reads

New functional test for the TFPIα cofactor activity of Protein S working in synergy with FV-Short.

J Thromb Haemost 2019 Feb 11. Epub 2019 Feb 11.

Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.

Essentials Protein S and FV-Short are synergistic cofactors to Tissue Factor Pathway Inhibitor α (TFPIα). An assay for the TFPIα synergistic cofactor activity of protein S with FV-Short was developed. The assay was specific for the synergistic TFPIα-cofactor activity of free protein S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14405DOI Listing
February 2019
1 Read

Inhibition of activated factor X; a new pathway in ameliorating carbon tetrachloride-induced liver fibrosis in rats.

J Biochem Mol Toxicol 2019 Feb 4:e22287. Epub 2019 Feb 4.

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.

Activated factor X has a central role in the coagulation activation and also contributes to chronic inflammation and tissue fibrosis. In this study, rivaroxaban, a direct factor X inhibitor, attenuates liver fibrosis induced by carbon tetrachloride (CCl ). Male rats were randomly allocated into three groups: a control group, CCl fibrotic group, and CCl +rivaroxaban (5 mg/kg) group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbt.22287DOI Listing
February 2019
1 Read

4--Methylhonokiol Influences Normal Cardiovascular Development in Medaka Embryo.

Molecules 2019 Jan 29;24(3). Epub 2019 Jan 29.

Department of Biomolecular Sciences, Division of Pharmacology, University of Mississippi, University, MS 38677, USA.

Although 4--Methylhonokiol (MH) effects on neuronal and immune cells have been established, it is still unclear whether MH can cause a change in the structure and function of the cardiovascular system. The overarching goal of this study was to evaluate the effects of MH, isolated from , on the development of the heart and vasculature in a Japanese medaka model in vivo to predict human health risks. We analyzed the toxicity of MH in different life-stages of medaka embryos. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules24030475DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384692PMC
January 2019
1 Read

Antibodies in the Treatment of Haemophilia A-A Biochemical Perspective.

Hamostaseologie 2019 Feb 29;39(1):36-41. Epub 2019 Jan 29.

Unité Mixte de Recherche Scientifique 1176, Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.

Replacement therapy has been proven effective in the management of bleedings in haemophilia A. Nevertheless, this approach comes with several shortcomings, like the need for frequent intravenous infusions and the development of neutralizing antibodies in 20 to 30% of the patients with severe haemophilia A replacement. This has led to the development of novel strategies to expand the spectrum of treatment options, some of which are based on antibody technology. Read More

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1677521
Publisher Site
http://dx.doi.org/10.1055/s-0038-1677521DOI Listing
February 2019
4 Reads

Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic Effect.

Cancers (Basel) 2019 Jan 5;11(1). Epub 2019 Jan 5.

Division of Haematology and Haematology Central Laboratory, CHUV, University Hospital of Lausanne, 1011 Lausanne, Switzerland.

Cancer patients develop a hypercoagulable state with a four- to seven-fold higher thromboembolic risk compared to non-cancer patients. Thromboembolic events can precede the diagnosis of cancer, but they more often occur at diagnosis or during treatment. After malignancy itself, they represent the second cause of death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11010046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356803PMC
January 2019

Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches.

Int J Mol Sci 2018 Dec 29;20(1). Epub 2018 Dec 29.

Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.

Myc (avian myelocytomatosis viral oncogene homolog) represents one of the most sought after drug targets in cancer. Myc transcription factor is an essential regulator of cell growth, but in most cancers it is overexpressed and associated with treatment-resistance and lethal outcomes. Over 40 years of research and drug development efforts did not yield a clinically useful Myc inhibitor. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/20/1/120
Publisher Site
http://dx.doi.org/10.3390/ijms20010120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337544PMC
December 2018
9 Reads

Reversal of Novel Anticoagulants in Emergent Surgery and Trauma: A Comprehensive Review and Proposed Management Algorithm.

Curr Pharm Des 2018 ;24(38):4540-4553

First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.

Non-vitamin K oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, are increasingly used for thromboembolism prevention. Contrary to older anticoagulants, such as coumadin, when antidotes existed and were broadly used in cases of emergent surgery and bleeding, antidotes for NOACs have not been developed until recently. Moreover, the monitoring of NOAC's anticoagulant effect varies across different hospital settings and the absence of a single test that can accurately predict the degree of anticoagulation achieved increases the uncertainty. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/168587/article
Publisher Site
http://dx.doi.org/10.2174/1381612825666181226150629DOI Listing
January 2018
4 Reads

Complete remission in a bleeding patient with idiopathic autoimmune factor X deficiency caused by non-neutralizing anti-factor X autoantibody.

Haemophilia 2018 Dec 20. Epub 2018 Dec 20.

Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hae.13675DOI Listing
December 2018
2 Reads

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration.

Front Vet Sci 2018 4;5:304. Epub 2018 Dec 4.

Department of Population Medicine and Diagnostic Science, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States.

Horses with inflammatory and infectious disorders are often treated with injectable heparin anticoagulants to prevent thrombotic complications. In humans, a new class of direct oral acting anticoagulants (DOAC) appear as effective as heparin, while eliminating the need for daily injections. Our study in horses evaluated apixaban, a newly approved DOAC for human thromboprophylaxis targeting activated factor X (Xa). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fvets.2018.00304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288471PMC
December 2018
3 Reads

Synthesis, characterization, molecular docking, analgesic, antiplatelet and anticoagulant effects of dibenzylidene ketone derivatives.

Chem Cent J 2018 Dec 6;12(1):134. Epub 2018 Dec 6.

Basic Sciences Department, College of Science and Health Professions-(COSHP-J), King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.

In this study dibenzylidene ketone derivatives (2E,5E)-2-(4-methoxybenzylidene)-5-(4-nitrobenzylidene) cyclopentanone (AK-1a) and (1E,4E)-4-(4-nitrobenzylidene)-1-(4-nitrophenyl) oct-1-en-3-one (AK-2a) were newly synthesized, inspired from curcuminoids natural origin. Novel scheme was used for synthesis of AK-1a and AK-2a. The synthesized compounds were characterized by spectroscopic techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13065-018-0507-1DOI Listing
December 2018
4 Reads

Factor X deficiency due to a compound heterozygosis between a new mutation (Gla72Asp) in exon 2 and an already known one (Gly154Arg) in exon 5: Factor X Mar del Plata 1).

Cardiovasc Hematol Disord Drug Targets 2018 Dec 11. Epub 2018 Dec 11.

Laboratorio de Hematologia, Sanatorio Allende y Departamento de Bioquimica Clinica, Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Cordoba. Argentina.

A compound heterozygote due to the association of a new mutation (Gla72Asp) with an already known mutation (Gly154Arg) of the FX gene is reported. The proposita is a 38 year old female who had a moderate bleeding tendency (menorrhagia, epistaxis, easy bruising). The proposita has never received substitution therapy but in the occasion of a uterine biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871529X19666181212103944DOI Listing
December 2018
1 Read

[Successful long-term management of ovarian bleeding and menorrhagia with prothrombin complex concentrate in a patient with congenital factor X deficiency].

Rinsho Ketsueki 2018;59(11):2428-2431

Department of Blood Coagulation, Ogikubo Hospital.

A female patient in her forties exhibited no evidence of abnormal bleeding at birth. At the age of 6 years, she experienced pain in bilateral thighs and knee joints without any occasion. Accordingly, the bleeding tendency was suspected, and the coagulation profile assessment revealed prolongation of the APTT (122 s). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.59.2428DOI Listing
January 2018
2 Reads

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?

Cancer Manag Res 2018 8;10:5423-5431. Epub 2018 Nov 8.

Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Purpose: Although several trials have demonstrated improved progression-free survival (PFS) with first-line regimens for HER2-negative metastatic breast cancer (mBC), overall survival (OS) benefit is elusive. We calculated required sample sizes to power for OS using published data from recent mBC trials.

Patients And Methods: Randomized superiority trials of first-line chemotherapy/targeted therapy for HER2-negative mBC including >150 patients, meeting the primary efficacy objective, and published in 2000-2018 were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S177240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235000PMC
November 2018
8 Reads

Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.

J Clin Pathol 2019 Mar 5;72(3):244-250. Epub 2018 Dec 5.

Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.

Aims: Clot waveform analysis (CWA) has been reported to extend the interpretation of clotting time measurement. The parameters obtained from successive derivatives of the clotting reaction curves reflect the rates of activation of individual coagulation factors, theoretically dissecting the cascade pathway. This study aims to assess the in vitro effects of direct thrombin inhibitors (DTIs) and activated factor X (FXa) inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2018-205517DOI Listing
March 2019
3 Reads

Probable Roles of Coagulation Cascade and Fibrinolysis System in the Development of Allergic Rhinitis.

Am J Rhinol Allergy 2019 Mar 6;33(2):137-144. Epub 2018 Dec 6.

3 Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.

Background: Dysregulation of the coagulation cascade and fibrinolysis system may play an etiologic role in many diseases. Allergic diseases such as bronchial asthma, atopic dermatitis, and conjunctivitis are also associated with fibrin accumulation caused by a change in hemostasis. However, only a few studies have dealt with the relationship between allergic rhinitis (AR) and the coagulation system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1945892418816015DOI Listing
March 2019
4 Reads

Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency.

Blood Coagul Fibrinolysis 2019 Jan;30(1):34-41

St. George's Haemophilia Centre, St. George's University Hospitals NHS Foundation Trust, London, UK.

: The objective was to examine the genotypic and phenotypic characteristics of individuals with hereditary factor X deficiency (FXD), a rare autosomal recessive bleeding disorder caused by mutations in the F10 gene located on chromosome 13q34-ter. To date, 149 F10 mutations have been identified as contributory to FXD. Three open-label phase 3 trials enrolled individuals with mild, moderate, or severe FXD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MBC.0000000000000787DOI Listing
January 2019
3 Reads

A rare presentation of homozygous factor X deficiency in a pregnant patient: A case report and review of the literature.

Haemophilia 2019 Jan 3;25(1):e57-e59. Epub 2018 Dec 3.

Universitaire Ziekenhuizen Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hae.13654DOI Listing
January 2019
2 Reads

Mud in the blood: Novel potent anticoagulant coagulotoxicity in the venoms of the Australian elapid snake genus Denisonia (mud adders) and relative antivenom efficacy.

Toxicol Lett 2019 Mar 28;302:1-6. Epub 2018 Nov 28.

FaunaVet Wildlife Consultancy, Glass House Mountains, QLD, 4518, Australia. Electronic address:

Due to their potent coagulotoxicity, Australian elapid venoms are unique relative to non-Australian members of the Elapidae snake family. The majority of Australian elapids possess potent procoagulant venom, while only a few species have been identified as possessing anticoagulant venoms. The majority of research to-date has concentrated on large species with range distributions overlapping major city centres, such as brown snakes (Pseudonaja spp. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxlet.2018.11.015DOI Listing
March 2019
3 Reads

Identification of Rfx6 target genes involved in pancreas development and insulin translation by ChIP-seq.

Biochem Biophys Res Commun 2019 Jan 30;508(2):556-562. Epub 2018 Nov 30.

Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China; Beijing Diabetes Institute, Beijing, 100730, China; Beijing Key Laboratory of Diabetes Research and Care, Beijing 100730, China. Electronic address:

Regulatory Factor X-box binding transcriptional factor 6 (Rfx6) plays an important role in the differentiation and development of pancreas in mammals. However, the direct target genes of Rfx6 to regulate this process were largely unknown. The present study aimed to investigate the function of Rfx6 on regulating pancreatic differentiation and development in a physiologically-relevant context. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2018.11.133DOI Listing
January 2019
2 Reads

Habu coagulotoxicity: Clinical implications of the functional diversification of Protobothrops snake venoms upon blood clotting factors.

Toxicol In Vitro 2019 Mar 22;55:62-74. Epub 2018 Nov 22.

Venom Evolution Lab, School of Biological Sciences, University of Queensland, St Lucia, QLD 4072, Australia. Electronic address:

Venom can affect any part of the body reachable via the bloodstream. Toxins which specifically act upon the coagulation cascade do so either by anticoagulant or procoagulant mechanisms. Here we investigated the coagulotoxic effects of six species within the medically important pit viper genus Protobothrops (Habu) from the Chinese mainland and Japanese islands, a genus known to produce hemorrhagic shock in envenomed patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tiv.2018.11.008DOI Listing
March 2019
2 Reads

The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies.

Thromb Res 2019 01 9;173:4-11. Epub 2018 Nov 9.

Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy. Electronic address:

Fusion with human serum albumin (HSA), which represents a well-established technique to extend half-life of therapeutic proteins, commonly exploits intervening peptide linkers as key components. Here, we explored the human coagulation factor X (FX) carboxyl-terminal region, previously demonstrated by us to be dispensable for secretion and coagulant activity, as a natural linker for fusion purposes. To test our hypothesis, we compared direct FX-HSA fusion with the designed FX-HSA fusion proteins mimicking the recombinant activated factor VII (rFVIIa)-HSA or factor IX (FIX)-HSA chimeras, both strongly dependent from artificial linkers. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00493848183060
Publisher Site
http://dx.doi.org/10.1016/j.thromres.2018.11.007DOI Listing
January 2019
14 Reads

Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.

J Thromb Haemost 2019 Jan 16;17(1):149-156. Epub 2018 Dec 16.

Division of Hematology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.

Essentials Protein Z (PZ) catalyzes PZ-dependent proteinase inhibitor (ZPI) inactivation of factor (F)Xa. Gene-deletion of PZ or ZPI improves coagulation in hemophilia (FVIII knockout) mice. A PZ blocking antibody enhances thrombin generation in human hemophilia plasma. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14337
Publisher Site
http://dx.doi.org/10.1111/jth.14337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322933PMC
January 2019
19 Reads

Development of a Highly Active Fluorescence-Based Detector for Yeast G Protein-Coupled Receptor Ste2p.

J Microbiol Biotechnol 2018 Oct;28(10):1589-1603

School of Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea.

Twenty analogs of [Orn,D-Ala]α-factor were synthesized and assayed for their biological activities: seven analogs of [Orn,X]α-factor, seven analogs of [X,D-Ala]α-factor, five analogs of [X,X,D-Ala]α-factor, and native α-factor (X = amino acids). Their biological activities (halo, gene induction, and affinity) were measured using Y7925 and LM102 and compared with those of native α-factor (100%). G protein-coupled receptor was expressed in strain LM102 containing pESC-LEU- vector. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4014/jmb.1805.04045DOI Listing
October 2018
10 Reads

Antithrombotic medications and their impact on fibrin clot structure and function.

Authors:
A Undas M Zabczyk

J Physiol Pharmacol 2018 Aug 7;69(4). Epub 2018 Nov 7.

Institute of Cardiology, Jagiellonian University Medical College, and the John Paul II Hospital, Cracow, Poland.

Fibrin constitutes a major protein component of intravascular thrombi in all locations. Fibrin formation and its functions are essential for physiological hemostasis and the pathologic thrombosis. Formation of dense fibrin networks which are relatively resistant to lysis is observed in patients with venous or arterial thromboembolism, including myocardial infarction, ischemic stroke and venous thromboembolism. Read More

View Article

Download full-text PDF

Source
http://jpp.krakow.pl/journal/archive/08_18/pdf/10.26402/jpp.
Publisher Site
http://dx.doi.org/10.26402/jpp.2018.4.02DOI Listing
August 2018
18 Reads

[Recombinant expression and purification of spider toxin, JZTX-51 and JZTX-26, from Chilobrachys jingzhao].

Sheng Wu Gong Cheng Xue Bao 2018 Oct;34(10):1668-1678

College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha 410128, Hunan, China.

To establish a simple, quick and effective method to get a large amount of spider toxin JZTX-26 (35 aa) and JZTX-51 (27 aa) with 3 disulfide bonds each, the mature peptides coding gene fragments were constructed and fused with maltose-binding protein (MBP) tag in an Escherichia coli expression vector pMAL-p2x. The recombinant constructs pMAL-jz26 and pMAL-jz51 were transformed and cultured in E. coli TB1 and BL21 (DE3). Read More

View Article

Download full-text PDF

Source
http://doi.cnki.net/Resolution/Handler?doi=10.13345/j.cjb.17
Publisher Site
http://dx.doi.org/10.13345/j.cjb.170529DOI Listing
October 2018
18 Reads

Differential Assessment of Factor Xa Activity and Global Blood Coagulability Utilizing Novel Dielectric Coagulometry.

Sci Rep 2018 Oct 31;8(1):16129. Epub 2018 Oct 31.

Department of Biofunctional Informatics, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

An easy-to-use assessment for activated factor X (FXa) is lacking despite its pivotal role in the coagulation. Dielectric blood coagulometry (DBCM) was recently invented as a novel assessment tool for determining the whole blood coagulability by measuring the temporal change in the permittivity of blood. We previously reported that it could evaluate the global blood coagulability. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-34229-6
Publisher Site
http://dx.doi.org/10.1038/s41598-018-34229-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208345PMC
October 2018
9 Reads

Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.

Melanoma Res 2019 02;29(1):99-101

Division of Pediatric Hematology-Oncology, Oncology Institute, Istanbul University.

Malignant melanoma is very rare in childhood. The approach to diagnosis and treatment in children has been adopted from adult guidelines. Vemurafenib is indicated in adults with BRAF V600 mutation-positive stage IIIc/IV melanoma and causes cutaneous adverse events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000537DOI Listing
February 2019
3 Reads

Hypertension and obesity moderate the relationship between β-amyloid and cognitive decline in midlife.

Alzheimers Dement 2019 Mar 25;15(3):418-428. Epub 2018 Oct 25.

Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.

Background: This study tested if central obesity, hypertension, or depressive symptoms moderated the relationship between β-amyloid (Aβ) and longitudinal cognitive performance in late middle-aged adults enriched for Alzheimer's disease (AD) risk.

Methods: Participants (n = 207; ages = 40-70 years; 73% parental AD) in the Wisconsin Registry for Alzheimer's Prevention study completed 3+ neuropsychological evaluations and a [C]PiB positron emission tomography scan or lumbar puncture. Linear mixed-effects regression models tested interactions of risk factor × Aβ × visit age on longitudinal Verbal Learning & Memory and Speed & Flexibility factor scores. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15525260183355
Publisher Site
http://dx.doi.org/10.1016/j.jalz.2018.09.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408972PMC
March 2019
10 Reads

The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.

Ther Adv Hematol 2018 Oct 10;9(10):319-334. Epub 2018 Oct 10.

Division of Pediatric Hematology/Oncology, Carmen and Ann Adams Department of Pediatrics, Children's Hospital of Michigan, 3901 Beuabien St, Detroit, MI 48201, USA.

Hemophilia A, characterized by impaired or absent expression of factor VIII, has long been managed direct factor replacement. Functionally, factor VIII acts as a cofactor for factor IXa and allows activation of factor X, which, in combination with factor V, generates thrombin. Bispecific antibodies such as emicizumab are recombinant, monoclonal antibodies capable of recognizing and binding to two distinct antigenic targets simultaneously; emicizumab binds factors IXa and X, resulting in spatial approximation and activation of factor X, thereby mimicking the actions of factor VIII. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620718799997DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187429PMC
October 2018
4 Reads

The transcription factor TpRfx1 is an essential regulator of amylase and cellulase gene expression in .

Biotechnol Biofuels 2018 8;11:276. Epub 2018 Oct 8.

State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, Guangxi Research Center for Microbial and Enzyme Engineering Technology, College of Life Science and Technology, Guangxi University, 100 Daxue Road, Nanning, 530004 Guangxi People's Republic of China.

Background: Perfect and low cost of fungal amylolytic and cellulolytic enzymes are prerequisite for the industrialization of plant biomass biorefinergy to biofuels. Genetic engineering of fungal strains based on regulatory network of transcriptional factors (TFs) and their targets is an efficient strategy to achieve the above described aim. produces integrative amylolytic and cellulolytic enzymes; however, the regulatory mechanism associated with the expression of amylase and cellulase genes in remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13068-018-1276-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174557PMC
October 2018
10 Reads

Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.

Anesth Analg 2018 Oct 12. Epub 2018 Oct 12.

Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland.

Background: Recombinant activated factor VII (rFVIIa) concentrate reduces allogeneic blood transfusions, but it may increase thromboembolic complications in complex cardiac surgery. The mixture of activated factor VII (FVIIa) and factor X (FX) (FVIIa/FX) (FVIIa:FX = 1:10) is a novel bypassing agent for hemophilia patients. We hypothesized that the combination of FX and FVIIa could improve thrombin generation (TG) in acquired multifactorial coagulation defects such as seen in cardiac surgery and conducted in vitro evaluation of FVIIa/FX in parallel with other coagulation factor concentrates using in vitro and in vivo diluted plasma samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1213/ANE.0000000000003858DOI Listing
October 2018
13 Reads

Protease-activated receptors are potential regulators in the development of arterial endofibrosis in high-performance athletes.

J Vasc Surg 2018 Oct 9. Epub 2018 Oct 9.

Laboratory for Clinical Thrombosis and Hemostasis, Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands.

Objective: High-performance athletes can develop symptomatic arterial flow restriction during exercise caused by endofibrosis. The pathogenesis is poorly understood; however, coagulation enzymes, such as tissue factor (TF) and coagulation factor Xa, might contribute to the fibrotic process, which is mainly regulated through activation of protease-activated receptors (PARs). Therefore, the aim of this explorative study was to evaluate the presence of coagulation factors and PARs in endofibrotic tissue, which might be indicative of their potential role in the natural development of endofibrosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07415214183163
Publisher Site
http://dx.doi.org/10.1016/j.jvs.2018.05.220DOI Listing
October 2018
15 Reads

Coagulotoxicity of (Lancehead Pit-Vipers) Venoms from Brazil: Differential Biochemistry and Antivenom Efficacy Resulting from Prey-Driven Venom Variation.

Toxins (Basel) 2018 Oct 11;10(10). Epub 2018 Oct 11.

Venom Evolution Lab, School of Biological Sciences, University of Queensland, St. Lucia, QLD 4072, Australia.

Lancehead pit-vipers ( genus) are an extremely diverse and medically important group responsible for the greatest number of snakebite envenomations and deaths in South America. (common lancehead), responsible for majority of snakebites and related deaths within the Brazilian Amazon, is a highly adaptable and widely distributed species, whose venom variability has been related to several factors, including geographical distribution and habitat type. This study examined venoms from four populations (Belterra and Santarém, PA; Pres. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6651/10/10/411
Publisher Site
http://dx.doi.org/10.3390/toxins10100411DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215258PMC
October 2018
3 Reads

The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions.

J Biomed Sci 2018 Oct 4;25(1):71. Epub 2018 Oct 4.

Institute of Biomedical Sciences, Academia Sinica, 128 Sec. 2, Academia Rd. Nankang, Taipei, 115, Taiwan, Republic of China.

Psychiatric disorders (such as bipolar disorder, depression, and schizophrenia) affect the lives of millions of individuals worldwide. Despite the tremendous efforts devoted to various types of psychiatric studies and rapidly accumulating genetic information, the molecular mechanisms underlying psychiatric disorder development remain elusive. Among the genes that have been implicated in schizophrenia and other mental disorders, disrupted in schizophrenia 1 (DISC1) and glycogen synthase kinase 3 (GSK3) have been intensively investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12929-018-0473-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171312PMC
October 2018
2 Reads

Acquired factor V inhibitor-related severe bleeding due to unformed prothrombinase complex.

Thromb Res 2018 11 20;171:81-83. Epub 2018 Sep 20.

Nagahama Institute of Bio-Science and Technology, Shiga, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2018.09.052DOI Listing
November 2018
30 Reads

Antiplatelet and anticoagulant activities of two phospholipase A2s purified from Cerastes cerastes venom: Structure-function relationship.

J Biochem Mol Toxicol 2018 Dec 21;32(12):e22219. Epub 2018 Sep 21.

Faculty of Biological Sciences, Laboratory of Cellular and Molecular Biology, USTHB, Bab Ezzouar, Algiers, Algeria.

This study aimed to elucidate anticoagulant/antiplatelet mechanisms of two previously purified PLA s from Cerastes cerastes venom, here, termed Cc -PLA and Cc -PLA . Both PLA s present close molecular weights of 13,534 and 13,430 Da and Isoectric pH (pI) 7.38 and 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbt.22219DOI Listing
December 2018
1.925 Impact Factor

Common Conditions Requiring Long-Term Anticoagulation in Neurosurgical Patients.

Neurosurg Clin N Am 2018 Oct;29(4):529-535

Department of Neurosurgery, Stanford University Medical Center, 300 Pasteur Drive Room R211, MC 5327, Stanford, CA 94305, USA. Electronic address:

Long-term anticoagulant therapy prevents thrombosis. Management of neurosurgical patients with conditions such as atrial fibrillation, mechanical heart valves, and other prothrombotic states necessitates application of a strategy to mitigate hemorrhagic complications of anticoagulation. Development of direct oral anticoagulants, which include the direct thrombin and factor X inhibitors, yields new considerations to be had, in particular, the introduction of reversal agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nec.2018.06.009DOI Listing
October 2018
1 Read

Anticoagulation in atrial fibrillation with factor X deficiency-A management dilemma.

Clin Case Rep 2018 Sep 22;6(9):1781-1785. Epub 2018 Jul 22.

Associates in Hematology and Oncology, P.C. Crozer Regional Cancer Center Upland Pennsylvania.

Factor X (FX) deficiency is a rare bleeding disorder. There is currently no clear guideline or recommendation for the appropriate selection of anticoagulation and management of patients with FX deficiency who require anticoagulation. We shared our experience in managing such patient, and we further discussed other possible treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1731DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132141PMC
September 2018
2 Reads

Caffeine and Sprint Cycling Performance: Effects of Torque Factor and Sprint Duration.

Int J Sports Physiol Perform 2019 Apr 19;14(4):426-431. Epub 2019 Feb 19.

Purpose: To investigate the influence of torque factor and sprint duration on the effects of caffeine on sprint cycling performance.

Methods: Using a counterbalanced, randomized, double-blind, placebo-controlled design, 13 men completed 9 trials. In trial 1, participants completed a series of 6-s sprints at increasing torque factors to determine the torque factor, for each individual, that elicited the highest (T) peak power output (PPO). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1123/ijspp.2018-0458DOI Listing
April 2019
5 Reads